Fortrea Clinical Research Unit Inc.
Dallas, Texas, 75247, United States
NCT Number: NCT06106334
The primary purpose of this study is to determine the effect of repeated administration of itraconazole on the pharmacokinetic (PK) profile of S-309309; and the PK of S-309309 following administration of S-309309 alone and co-administration with itraconazole
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Dallas, Texas, 75247, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Administered as oral capsules
Administered as oral capsules
Time frame: Up to 2 weeks postdose on Days 1, 19
Time frame: Up to 2 weeks postdose on Days 1, 19
Time frame: Up to 2 weeks postdose on Days 1, 19
Time frame: Up to 5 weeks
Shionogi
Industry
A Crossover, Phase 1, Open-label, One-arm Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Male and Female Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00862433
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT01352949
Body Weight, Bone Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT02977403
Behavior, Behavior, Animal
Bethesda, Maryland, United States
View Trial DetailsNCT04259801
Body Weight, Diabetes Mellitus
Groningen, Netherlands
View Trial Details